IP Library Granted Patent US 7,955,822
Granted Patent B2
US 7,955,822 · App. 12/819,700 · Granted Jun 7, 2011

Detection of nucleic acids and proteins

Assignee: Predictive Biosciences Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,955,822
App. No.
12/819,700
Granted
Jun 7, 2011
Kind
B2
Abstract

The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay.

Claims (26)

1. A method of detecting multiple analytes in a sample, the method comprising the steps of:

obtaining a sample comprising at least one target nucleic acid and at least one target protein;

introducing an aptamer that binds to the target protein in the sample; and

conducting a single assay, wherein the assay detects both the target nucleic acid and the target protein, the assay comprising: removing unbound aptamer-protein complex from bound aptamer-protein complex performing PCR on the target nucleic acid; performing PCR on the aptamer protein complex; introducing a first detectably labeled probe that binds to the amplified target nucleic acid; introducing a second detectably labeled probe that binds to the amplified aptamer protein complex; detecting the first probe thereby detecting the nucleic acid in the sample; and detecting the second probe that is bound to the amplified aptamer protein complex thereby detecting the protein in the sample.

2. The method according to claim 1 , further comprising quantifying the target nucleic acid.

3. The method according to claim 1 , further comprising quantifying the target protein.

4. The method according to claim 1 , further comprising quantifying the target nucleic acid and the target protein.

5. The method according to claim 4 , wherein the quantifying comprises:

performing real time PCR on the nucleic acid; and

performing real time PCR on the aptamer, wherein quantifying the amplified aptamer quantifies the target protein.

6. The method according to claim 1 , wherein the target nucleic acid is associated with a disease.

7. The method according to claim 6 , wherein the disease is cancer.

8. The method according to claim 6 , wherein the target nucleic acid is selected from the group consisting of: FGFR3, K-ras, K-ras2, APC, DCC, TP53, PRC1, NUSAPI1, CAPZ, PFKP, EVER1, FLT1, ESPL1, AKAP2, CDC45L, RAMP, SYNGR2, NDRG1, ZNF533, and hypermethylated nucleic acid.

9. The method according to claim 1 , wherein the target protein is associated with a disease.

10. The method according to claim 9 , wherein the disease is cancer.

11. The method according to claim 9 , wherein the target protein is selected from the group consisting of: MMP-2, MMP-9, MMP9/NGAL complex, MMP/TIMP complex, MMP/TIMP1 complex, ADAMTS-7, ADAM-12, thymosin 15, thymosin 16, profilin, prohibitin, ubiquitin, tropomyosin, Cyr61, cystatin B, and chaperonin 10.

12. A method of detecting multiple analytes in a sample, the method comprising the steps of:

obtaining a sample comprising at least one target nucleic acid and at least one target protein;

introducing to the sample an aptamer that binds the target protein; and

conducting a single assay that detects and quantifies the target nucleic acid and the target protein, wherein the assay comprises removing unbound aptamer-protein complex from bound aptamer-protein complex: performing real time PCR on the nucleic acid, thereby quantifiably detecting the nucleic acid in the sample; and performing real time PCR on the aptamer-protein complex, thereby quantifiably detecting the aptamer-protein complex which quantifiably detects the target protein in the sample.

13. The method according to claim 12 , wherein the target nucleic acid is associated with a disease.

14. The method according to claim 13 , wherein the disease is cancer.

15. The method according to claim 13 , wherein the target nucleic acid is selected from the group consisting of: FGFR3, K-ras, K-ras2, APC, DCC, TP53, PRC1, NUSAPI1, CAPZ, PFKP, EVER1, FLT1, ESPL1, AKAP2, CDC45L, RAMP, SYNGR2, NDRG1, ZNF533, and hypermethylated nucleic acid.

16. The method according to claim 12 , wherein the target protein is associated with a disease.

17. The method according to claim 16 , wherein the disease is cancer.

18. The method according to claim 16 , wherein the target protein is selected from the group consisting of: MMP-2, MMP-9, MMP9/NGAL complex, MMP/TIMP complex, MMP/TIMP1 complex, ADAMTS-7, ADAM-12, thymosin 15, thymosin 16, profilin, prohibitin, ubiquitin, tropomyosin, Cyr61, cystatin B, and chaperonin 10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2014
From: PREDICTIVE BIOSCIENCES, INC.
To: PHYSICIANS CHOICE LABORATORY SERVICES, LLC
Reel/Frame 032705/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2010
From: SHUBER, ANTHONY; CHIU, EUGENE
To: PREDICTIVE BIOSCIENCES CORPORATION
Reel/Frame 025076/0200 →
Continuity (3)
Continuation In Part 12034698 · Feb 21, 2008
Provisional Application 60972507 · Sep 14, 2007
Related Publication 20110014618A1 · Jan 20, 2011